e-learning
resources
Barcelona 2010
Monday, 20.09.2010
Aetiology of lower respiratory tract infections and treatment in special situations
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The effect of addition of macrolide to a beta-lactam antibiotic on treatment success in patients with moderately severe community acquired pneumonia
O. N. Hatipoglu, S. Uysal, G. Altiay, N. Sut, E. Tabakoglu (Istanbul, Edirne, Turkey)
Source:
Annual Congress 2010 - Aetiology of lower respiratory tract infections and treatment in special situations
Session:
Aetiology of lower respiratory tract infections and treatment in special situations
Session type:
Thematic Poster Session
Number:
3006
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
O. N. Hatipoglu, S. Uysal, G. Altiay, N. Sut, E. Tabakoglu (Istanbul, Edirne, Turkey). The effect of addition of macrolide to a beta-lactam antibiotic on treatment success in patients with moderately severe community acquired pneumonia. Eur Respir J 2010; 36: Suppl. 54, 3006
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Related content which might interest you:
Survival benefit of beta-lactam plus macrolide combined therapy versus beta-lactam plus quinolones in hospitalized community-acquired pneumonia
Source: International Congress 2016 – Community-acquired pneumonia: update on prognostic factors and therapeutic strategies
Year: 2016
Cost-effective antibiotic management of community acquired pneumonia
Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=198
Year: 2004
Monotherapy with β-lactamic antibiotics or macrolides vs their combination for the treatment of community acquired pneumonia (CAP)
Source: Annual Congress 2008 - Lower respiratory tract infection: from outbreak to prognostic tests
Year: 2008
Active monitoring of adverse drug reactions to the use of beta-lactam antibiotics in the treatment of community-acquired pneumonia
Source: Virtual Congress 2020 – Cardiovascular and pulmonary complications of respiratory infections
Year: 2020
The etiology and antimicrobial drugs resistance of microorganisms in patients with community-acquired pneumonia
Source: Eur Respir J 2006; 28: Suppl. 50, 2s
Year: 2006
The efficiency of levofloxacin in the therapy of community acquired pneumonia
Source: Eur Respir J 2006; 28: Suppl. 50, 5s
Year: 2006
Antibiotic resistance and clinical outcomes: the CAPNETZ experience
Source: Annual Congress 2006 - PG1 - Respiratory infections: pneumonia/antibiotic resistance and clinical outcome of lower respiratory tract infections
Year: 2006
Importance of appropriate initial antibiotic therapy and de-escalation in the treatment of nosocomial pneumonia
Source: Eur Respir Rev 2007; 16: 33-39
Year: 2007
Frequency of antibiotic resistance and outcomes in severe community acquired pneumonia due to
Streptococcus pneumoniae
Source: Annual Congress 2009 - Aetiology and treatment of community-acquired pneumonia
Year: 2009
Impact of reducing antibiotic treatment on inflammation among patients with community-acquired pneumonia.
Source: International Congress 2019 – Prognosis in bacterial and viral pneumonia
Year: 2019
Broad-spectrum antibiotic use and poor outcomes in community-onset pneumonia
Source: International Congress 2018 – Improving the outcomes of community-acquired pneumonia
Year: 2018
Improving outcome in elderly patients with pneumonia
Source: Annual Congress 2005 - Antibiotic therapy: short- and long-term outcomes in LRTI
Year: 2005
Broad-spectrum antibiotic use and poor outcomes in community-onset pneumonia: a cohort study
Source: Eur Respir J, 54 (1) 1900057; 10.1183/13993003.00057-2019
Year: 2019
Biological resistance to beta-lactamic antibiotics in patients with respiratory infection in the prediction of efficiency of antibacterial therapy
Source: Virtual Congress 2020 – Lower respiratory tract infections in clinical practice
Year: 2020
Frequency of side effects in antibiotic treatment for pneumonia
Source: International Congress 2019 – Clinical challenges in respiratory infection
Year: 2019
Antibiotic treatment for nosocomial pneumonia
Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=211
Year: 2004
The impact of empiric antibacterial therapy on mortality for patients hospitalized with community-acquired pneumonia (CAP)
Source: Eur Respir J 2006; 28: Suppl. 50, 733s
Year: 2006
Comparison of treatment outcomes in community-acquired pneumonia patients treated with beta lactam-macrolide combination versus fluoroquinolone monotherapy
Source: Annual Congress 2012 - Management of severe respiratory infections
Year: 2012
The use of piperacillin/tazobactam for treatment of pneumonia in neutropenic patients
Source: Annual Congress 2010 - Aetiology of lower respiratory tract infections and treatment in special situations
Year: 2010
The approach to antibiotic treatment in community-acquired pneumonia
Source: Annual Congress 2008 - MP14 - The approach to antibiotic treatment in community-acquired pneumonia
Year: 2008
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept